Guidance Notes on the Management of Safety Information and Product Complaints Digital Activities

On 27 April 2021 the Association of the British Pharmaceutical Industry (ABPI) published the informal guidance notes.

Digital activities contain digitised content that can be transmitted over the internet or computer networks. Digital activities are used by individuals and organisations as a component of overall communication with patients and customers to create or raise awareness about diseases and treatments. Pharmaceutical companies also use digital activities for corporate awareness, clinical trial enrolment, additional risk minimisation activities, patient support programmes, and treatment and prevention of diseases.

These guidance notes refer to the collection and management of SI/PC from digital activities, which have been implemented for legitimate business purposes. This includes company sponsored, owned or controlled digital activities (e.g., all company-owned social media sites used for business campaigns and use of non-company-sponsored websites).

These guidance notes are relevant for all company employees using digital activities, including persons retained by way of contract with third parties (excluding individual personal use of digital activities).

Read the pdf 
Copyright Widler & Schiemann AG 2020. All Rights Reserved. /